Chairs: C.H. Bangma, NL - J. Hugosson, SE
Co-Chair: L. Klotz, CAN
Honorary Chair: L.J. Denis, BE
ESO Prostate Cancer Programme Coordinator: R. Valdagni, IT
Scientific Coordinators: M.J. Roobol, NL - S. Carlsson, SE
Over the years, there has been increasing acceptance of active surveillance as an alternative to radical treatment for men with low risk prostate cancer.
Unless the over-diagnosis of indolent prostate cancer is reduced by alternative diagnostic strategies, active surveillance will continue to play an important role.
The challenge is to determine how new imaging methods and biomarkers can improve patient selection and how to incorporate drugs into active surveillance programmes.
ESO’s second Inside Track Conference “Active surveillance for Low Risk Prostate Cancer”, organized in collaboration with EAU and endorsed by Europa Uomo, aims at being an interactive educational activity in which attendees will enjoy presentations by internationally renowned researchers on active surveillance, who have helped develop and evaluate technologies that may change the selection and monitoring of patients.
Furthermore workshops will allow you to discuss a few selected hot topics with the top experts in that field. The remarks and conclusions of the workshops will give important insights into active surveillance practices applied in various countries.
When completing your registration form you will be asked to choose which workshop you would like to attend.
We would like to thank the European Association of Urology (EAU) and Europa Uomo for their participation and also, on behalf of the Scientific Coordinators, the Co-Chair, and the organizing team, we invite you to participate and contribute to a productive and enjoyable conference
ESO Prostate Cancer Programme Coordinator
• Overdetection and overtreatment
• Active Surveillance - the worldwide experience
• Selection and monitoring for Active Surveillance
• Application of emerging technology and biomarkers for screening, surveillance and treatment
• Quality of Life of men on Active Surveillance
• Active Surveillance or focal therapy: a thorny issue
• To define the state of the art of Active Surveillance for prostate cancer
• To evaluate the application of Active Surveillance in daily clinical practice
• To determine the future research trends within the uro-oncologic community
• To evaluate the options of Active Surveillance and focal therapy
Rita De Martini
Prostate Cancer Programme
European School of Oncology - Milan (Italy)
Telephone: +39 02 85464527
Facsimile: + 39 02 85464545
Programme, organisation and abstracts:
Rita De Martini (email@example.com) - Tel:+39 02 85464527 - Fax: +39 02 85464545
Elena Fiore (firstname.lastname@example.org) - Tel. + 39 02 85464529 - Fax: +39 02 85464545
MCI Amsterdam’s Hotel Operations team at: email@example.com
Beurs van Berlage
Damrak 243 - 1012 ZJ Amsterdam, NL
Beurs van Berlage is in a 5 minutes walk from the Amsterdam railway station.
In the Golden Age Amsterdam was the first place in the world to create a fixed location for the trade in stocks and shares (1611). The shares of the very first limited liability company in the world to be traded were those of the Dutch East India Company (Verenigde Oost-Indsche Compagnie, abbreviated to VOC).
Three hundred years later Berlage built the third Amsterdam Stock Exchange (1903); a building that generated a lot of controversy and, today, is considered the beginning of modern Dutch architecture.
CME ACCREDITATION AND CERTIFICATES
Participants will be issued a certificate of attendance through the event-dedicated website and after completing the evaluation questionnaire.
The Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME) have acknowledged the quality of the scientific programme and its educational value. The Active Surveillance Conference has been assigned 12 European Continuing Medical Education Credits (ECMEC).
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at
The granted credits will be recognised by EBU (European Board of Urology) accreditation system.
EAU members may inform ESO on their interest in having the credits recognised by EBU. On their notification, ESO will provide EU-ACME office with the member’s details for the registration in the accreditation system.
The official language of the Conference is English. No simultaneous translation will be provided.
Your name badge is the only official evidence of registration and should be worn at all times during the Conference.
The organisers bear no responsibility for untoward events in relation with the participation at the Conference. Participants are advised to take out their own personal and travel insurance coverage.
Free Wi-Fi internet access in all areas of the Conference venue is available.
FILMING, AUDIO-TAPING AND PHOTOGRAPHS
Please note that capturing contents of the sessions is prohibited.
REGISTRATION DESK, OPENING HOURS
Friday, 21 February (7:30 - 17:30)
Saturday, 22 February (7:30 - 17:30)
EXHIBITION OPENING HOURS
Friday, 21 February (8:00 - 17:30)
Saturday, 22 February (8:00 - 17:30)
Members of the faculty are invited to refer to the Speakers Room.
Public transport and taxis
The Beurs van Berlage is easily accessible by public transport. The Central Station is located a mere 300 m away. Upon leaving Central Station you can already see our building in the distance in front of you, along the main street called Damrak, leading into the citycenter.
The Dam/De Bijenkorf stop is the nearest tram stop. The following trams stop here: 4, 9, 16, 24, 25. For further information: www.gvb.nl
There are taxi stands directly in front of the Beurs van Berlage, at the Damrak. Call Taxi Centrale Amsterdam to order a cab, 0031 20 - 777 77 77.
Schiphol Amsterdam International Airport
Coming from Schiphol Airport, your can reach Beurs van Berlage by train or by taxi.
Train: You can buy a ticket in the Schiphol Arrival Hall for Amsterdam Centraal Station. Interval: 4 Trains per hour. Trainride takes approx. 15 minutes. For details to reach our building from Centraal Station: see above
Taxi: Destination "Beurs van Berlage", adress: Damrak 243. Approx. 25 minutes, depending on traffic.
The Beurs van Berlage is 20 minutes away from the A10 Ring road.
There is a number of large multi-storey car parks in the immediate vicinity of the Beurs van Berlage:
- De Bijenkorf multi-storey; 400 spaces (right next to the Beurs van Berlage) Parkeergarage De Bijenkorf - Q Park
- P1 Central Station multi-storey; 465 spaces (5-minute walk) Parkeergarage Centraal Station - P1
- Nieuwezijds Kolk multi-storey; 400 spaces (5-minute walk) Parkeergarage Nieuwezijds Kolk
- Oosterdok multi-storey; 250 spaces (10-minute walk) Oosterdok Parking
It is virtually impossible to park anywhere on the road near the Beurs van Berlage.
|Please click here to download the "Invitation to Sponsors" brochure.|
|ESO wishes to extend its appreciation to the following sponsors for having granted their participation and support to the Conference |
| || |
ESTRO MULTIDISCIPLINARY TEACHING COURSE ON PROSTATE CANCER
Amsterdam, 23-27 February 2014
Thanks to ESO-ESTRO collaboration, the ESTRO Multidisciplinary Teaching Course on Prostate Cancer will also be held in Amsterdam on the days following the ESO Conference “Active Surveillance for Low Risk Prostate Cancer”, offering a unique opportunity to participants to attend both educational events.
The Course, chaired by Alberto Bossi (FR) and Alberto Briganti (IT) will discuss the management of localized, locally advanced and disseminated prostate cancer. It stresses the importance of multidisciplinary teamwork, where each sub-discipline is interrelated and information exchange is vital.
Participants attending both the ESO Conference and the ESTRO Course will benefit from reciprocal discounts on the registration fees.
Specifically, participants who are registered at the ESTRO Course will be granted the fee of EUR 200 (by the early rate deadline) to register for the ESO Conference. Reciprocally, participants registered at the ESO Conference will be granted the fee of EUR 450 to register to the ESTRO Course.
Further information on the Course are available at: www.estro.org
C.H. Bangma, Department of Urology, Erasmus Medical Center, Rotterdam, NL
L. Bellardita, Prostate Cancer Programme, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
A. Briganti, Urological Institute, Ospedale San Raffaele, Milan, IT
S. Carlsson, Department of Surgery (Urology Service), Memorial Sloan- Kettering Cancer Center, New York, US and Department of Urology, Sahlgrenska Academy at the University of Goteborg, SE
P.R. Carroll, Department of Urology, UCSF School of Medicine, San Francisco, US
R. R. Damm, Europa Uomo, BE
L.J. Denis, Europa Uomo, Antwerp, BE
J. Hugosson, Department of Urology, Sahlgrenska Academy at the University of Göteborg, SE
G. Jenster, Department of Urology, Erasmus Medical Center, Rotterdam, NL
Y. Kakehi, Department of Urology, Kagawa University Faculty of Medicine, Kagawa, JP
L.H. Klotz, Division of Urology, Sunnybrook Health Sciences Centre, Toronto, CA
I. Korfage, Division of Epidemiology, Department of Public Health, Erasmus Medical Center, Rotterdam, NL
A. Lane, School of Social and Community Medicine, University of Bristol, Bristol, GB
S. Loeb, Department of Urology and Population Health, New York University, New York, US
C. Moore, Division of Surgical and Interventional Science, University College London, London, GB
T. Pickles, Department of Radiation, British Cancer Agency, Vancouver, CA
H. Randsdorp, Europa Uomo, Antwerp, BE
A. Rannikko, Department of Urology, Helsinki University Hospital, Helsinki, FI
S. Roemeling, Department of Urology, University Medical Center, Groningen, NL
M.J. Roobol, Department of Urology, Erasmus University Medical Center, Rotterdam, NL
B.J. Trock, Department of Urology, Johns Hopkins School of Medicine, Baltimore, US
R. Valdagni, ESO Prostate Cancer Programme / Prostate Cancer Programme and Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R. Van den Bergh, Department of Urology, University Medical Centre, Utrecht, NL
H. Van der Poel, Department of Urology, Netherlands Cancer Institute, Amsterdam, NL
H. Van Poppel, Department of Urology, University Hospital of the KU, Leuven, BE
A. Villers, Department of Urology, Hôpital Huriez, Centre Hospitalier Regional Universitaire, Lille, FR
H. Wijkstra, Department of Urology, Academic Medical Center University Hospital, Amsterdam, NL
DISCLOSURE OF CONFLICT OF INTEREST
Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the above mentioned event. Potential conflict of interest are considered any of the following:
|• ||Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the statement process;|
|•||Any financial interest in or arrangement with a competing company;|
|•||Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the statement process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.|
Chris Bangma: No significant relationships.
Lara Bellardita: No significant relationships.
Alberto Briganti: No significant relationships.
Sigrid Carlsson: No significant relationships.
Peter Robert Carroll: Genomic Health: consultant or advisory board member, research support, travel support, honorary lecture. Takeda, Janssen, Intuitive, Teva: travel support, honorary lecture.
Ralf-Rainer Damm: No significant relationships.
Louis Denis: No significant relationships.
Jonas Hugosson: No significant relationships.
Guido Jenster: Philips Research: research support. Janssen Pharmaceutica: research support.
Yoshiyuki Kakehi: No significant relationships.
Laurence Klotz: No significant relationships.
Ida Korfage: No significant relationships.
Athene Lane: No significant relationships.
Stacy Loeb: No significant relationships.
Caroline Moore: No significant relationships.
Tom Pickles: No significant relationships.
Hans Randsdorp: No significant relationships.
Antti Rannikko: No significant relationships.
Stijn Roemeling: No significant relationships.
Monique Roobol: No significant relationships.
Bruce Trock: No significant relationships.
Riccardo Valdagni: Bayer SpA: consultant or advisory board member. Amgen SpA: consultant or advisory board member. Jannssen: consultant or advisory board member.
Roderick van den Bergh: No significant relationships.
Henk Van der Poel: No significant relationships.
Hein Van Poppel: No significant relationships.
Arnauld Villers: No significant relationships.
Hessel Wijkstra: No significant relationships.
Welcome and objectives
|Prostate Cancer Programme - European School of Oncology|
R. Valdagni, IT
|OVER-DETECTION AND OVER-TREATMENT |
Chairs: J. Hugosson, SE - B. Trock, US
Setting the stage: over-detection in cancer
How to reduce the number needed to treat in prostate cancer screening
SELECTION AND MONITORING FOR ACTIVE SURVEILLANCE
Repeated biopsies: complications
|How accurately can MRI detect indolent disease? |
Triggers for reclassification in ongoing studies
|The image based targeted biopsy: what are criteria of indolence? |
C. Moore, UK
|Contrast enhanced ultrasound. Toy or tool? |
H. Wijkstra, NL
|How to evaluate intermediate outcomes in men for active surveillance? |
P. Carroll, US
Panel discussion: pitfalls and criticism of active surveillance
|Lunch and Poster Session|
Best poster presentations
|APPLICATION OF EMERGING TECHNOLOGY AND BIOMARKERS FOR SCREENING, SURVEILLANCE AND TREATMENT |
Chairs: T. Pickles, CA - A. Ranniko, FI
Biomarkers of indolent and aggressive prostate cancer - Application to active surveillance
Genomic and transcriptomic fingerprinting of prostate biopsies
Risk based prediction models for indolence: what is needed to incorporate new parameters?
Can MRI replace serial biopsies, and how to prove that?
|Panel discussion: Emerging technology and biomarkers: indolent or aggressive disease? |
Chairs: T. Pickles, CA - A. Ranniko, FI
Panelists: B. Trock, US - G. Jenster, NL - S. Loeb, US - C. Moore, GB
Questions and answers
Panel discussion: When to change current active surveillance protocols?
Focal therapy vs active surveillance
|THE QUALITY OF LIFE OF MEN ON ACTIVE SURVEILLANCE |
Chairs: L. Bellardita, IT - H. Randsdorp, BE - S. Roemeling, NL
Quality of life outcome in active surveillance PRIAS - The Netherlands
|Living with untreated prostate cancer: predictors of poor quality of life - PRIAS Quality of Life Study at Milan National Cancer Institute |
L. Bellardita, IT
|Men’s experience of long term active surveillance - The PROTECT trial |
A. Lane, GB
|The patients’ perspective on active surveillance - The European Support |
R.R. Damm, BE
Panel discussion: The quality of life of men on active surveillance
|Movember Lecture - “The global action programme dealing with active surveillance” |
C.H. Bangma, NL
Simultaneous Workshops (Workshops rooms are located at first floor)
Workshop #1 (Room: Berlagezaal)
|Workshop #2 (Derkinderen kamer)|
Overview of the global active surveillance studies / ongoing protocols
(B. Trock, US - R. Van den Bergh, NL)
|Workshop #3 has been cancelled due to the small number of participants |
Randomized clinical trials - How to incorporate agents into active surveillance programmes
(C.H. Bangma, NL - Y. Kakehi, JP)
Workshop #4 (Rode Kamer)
|Workshop #5 (Mendes de Costa kamer)|
What studies need to be done to define indolence by emerging technology and biomarkers?
(C. Moore, GB - L. Klotz, CA)
Reports from individual Working Groups and Discussion
|Discussion by all - Consensus building|
Chairs: C.H. Bangma, NL - J. Hugosson, SE
|Closing remarks |
C.H. Bangma, NL - J. Hugosson, SE
|Poster SessionAbstracts received by participants have been considered and selected for poster presentation only, except the two best abstracts posters that will be presented both as posters and as a 10 minute oral presentation on Friday 21 February. |
Accepted absrtracts will be published in the event’s dedicated website.
|1 ||Quality of life for men on active surveillance: how does health status really change? Maria Francesca Alvisi, IT|
|3||Active surveillance for prostate cancer: a comparison of Japan and the Netherlands. Leonard Bokhorst, NL|
|4||Towards an evidence based definition of very low risk prostate cancer. Ola Bratt, SE|
|5||Trans Perineal Prostate Biopsy outperforms TRUS biopsy in selecting truly low risk men for Active surveillance. Gabriele Cozzi, IT|
|6||The risk of MRI invisible prostate cancer in active surveillance. David Eldred-Evans, UK|
|7||Men’s perspectives on providing decision support for early detection of prostate cancer. Annelies Engelen, BE|
|8||Tumour grading and localisation errors comparing transrectal ultrasound-guided biopsy to radical prostatectomy and implications for active surveillance. Arveen Kalapara, AU|
|9||TRUS biopsy with anterior needles improves detection and localisation of prostate cancer in men undergoing active surveillance. Arveen Kalapara, AU|
|10||Surgical outcomes of patients who fail active surveillance for localised prostate cancer in an Australian population. Arveen Kalapara, AU|
|11||Current Trend of Incidence in Latent Prostate Cancer in Japan. Masahito Kido, JP|
|12||Transperineal biopsy related erectile dysfunction in Active Surveillance. Janette Kinsella, UK|
|13||Multiple transperineal prostate biopsies can impact on long-term erectile dysfunction. Janette Kinsella, UK|
|14||Urine biomarkers in prostate cancer patients on active surveillance. Milan Kral, CZ|
|15||Small non-coding RNAs as markers of recurrent prostate cancer. Elena Martens-Uzunova, NL|
|18 ||CCP score stratifies risk for prostate cancer patients at biopsy: initial commercial results. Marcello Paglione, IT|
|19||How does Histoscan Imaging compare to Multiparametric MRI in the detection of Prostate Cancer lesions. Neophytos Petrides, UK|
|20||Imaging guided active surveillance. What is the value of diffusion weighted and contrast enhanced MRI sequences? Neophytos Petrides, UK|
|21||How to measure Prostate Cancer lesion volume. Lessons learned from the use of different sequences. Neophytos Petrides, UK|
|22||Different predictors of upgrading and upsizing at 1-year repeat biopsy in low-risk prostate cancer patients on active surveillance: validation of a model. Tiziana Rancati, IT|
|24||Is the percent free to total PSA ratio a good predictor for prostate cancer upgrading after 1 year in men on active surveillance? Jolanda Salman, NL|
|26||Longitudinal assessment of general health related QOL in patients undergoing active surveillance (AS) for low risk prostate cancer: interim results of the PRIAS-JAPAN cohorts. Mikio Sugimoto, JP|
|27||SIUrO-PRIAS-ITA project: three year experience on active surveillance. Riccardo Valdagni, IT|
|28||Rule-based versus probabilistic selection for active surveillance for prostate cancer. Lionne Venderbos, NL|
|29||An in-silico model to identify the best predictors of Quality of Life in Active Surveillance. Silvia Villa, IT|
|30||MRI use prior to prostate biopsy in a german tertiary care centre: A plea for standardization. Lars Budäus, DE|
The deadline for submission is passed (10 December 2013)
Participants are invited to submit an abstract on research relating to the identification of potential indolent prostate cancer or on clinical studies relating to active surveillance of prostate cancer.
Abstracts will be considered for poster presentations only, except the two best abstracts posters which will be presented both as posters and as a 10-minute oral presentation on Friday, 21 February 2013. The two best abstracts will furthermore be awarded a prize of € 200.
Ample opportunity will be given to the conference participants to view all posters. The Chair of the Poster Session will visit all posters and participants will be able to give a short oral explanation of the research described (no slides). The Poster Session is scheduled on day, time.
Accepted abstracts will be published in the event’s dedicated website.
• The abstracts should be limited to 2000 characters, including the title.
• The title should be in lower case letters
• Each author should be listed with First name, followed by Family Name
• The first author should be underlined (first author = corresponding author and presenter)
• List affiliation after the author’s list
• The full address with e-mail address, phone and fax number of the first author (+corresponding author and presenter) must be provided. The first author will receive an acknowledgment of receipt and all subsequent communication by e-mail
• For abstracts accepted for poster presentation and best abstract oral presentation, the first author will be the presenting author and is requested to register and participate in the Conference
• It is responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made
The acknowledgement of receipt of abstract will follow the submission. The abstract submission outcome will be notified by 13 December 2013 to the first author who will be required to register to the Conference (early registration deadline, 20 December 2013).